Bowman-Birk Inhibitor Concentrate

Drug Profile

Bowman-Birk Inhibitor Concentrate

Alternative Names: BBI; BBIC; Bowman-Birk Inhibitor

Latest Information Update: 01 May 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class
  • Mechanism of Action Chymotrypsin inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Benign prostatic hyperplasia; Orofacial cancer

Most Recent Events

  • 06 May 1998 Phase-II clinical trials for Benign prostatic hyperplasia in USA (Unknown route)
  • 21 Apr 1997 Phase-II clinical trials for Orofacial cancer in USA (Unknown route)
  • 21 Apr 1997 Preclinical development for Benign prostatic hyperplasia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top